-transparent.png){kind=logo}
We tested the combination of cisplatin, amsacrine, and mitoguazone as salvage treatment for patients with advanced unfavorable non-Hodgkin's lymphomas. An objective response rate of 43% was noted in 30 evaluable patients, but all responses were partial and the median duration of response was only 2 months. Toxicity included life-threatening and fatal leukopenia and severe gastrointestinal intolerance. We conclude that this combination chemotherapy regimen is not a valuable salvage treatment for patients with non-Hodgkin's lymphoma.
Related Publications
B W Dana, and
S E Jones, and
C Coltman, and
W J Stuckey
December 1990,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
B W Dana, and
S E Jones, and
C Coltman, and
W J Stuckey
December 1987,
Cancer treatment reports,
B W Dana, and
S E Jones, and
C Coltman, and
W J Stuckey
January 1994,
Hematological oncology,
B W Dana, and
S E Jones, and
C Coltman, and
W J Stuckey
July 1982,
Cancer treatment reports,
B W Dana, and
S E Jones, and
C Coltman, and
W J Stuckey
April 1986,
Cancer treatment reports,
B W Dana, and
S E Jones, and
C Coltman, and
W J Stuckey
December 1977,
Cancer treatment reports,
B W Dana, and
S E Jones, and
C Coltman, and
W J Stuckey
May 1991,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
B W Dana, and
S E Jones, and
C Coltman, and
W J Stuckey
September 1977,
Cancer treatment reports,
B W Dana, and
S E Jones, and
C Coltman, and
W J Stuckey
May 1985,
Cancer treatment reports,
B W Dana, and
S E Jones, and
C Coltman, and
W J Stuckey
October 2000,
Anti-cancer drugs,
